Aclaris Therapeutics to Attend Upcoming Investor Conferences
May 10 2018 - 5:00PM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led
biopharmaceutical company committed to identifying, developing, and
commercializing innovative therapies to address significant unmet
needs in aesthetic and medical dermatology and immunology, today
announced that management will attend the following conferences:
- Management will host investor meetings during the Bank of
America Merrill Lynch’s 2018 Healthcare Conference in Las Vegas, NV
on Wednesday, May 16, 2018.
- Dr. Neal Walker, President and Chief Executive Officer, will
present at the Jefferies 2018 Healthcare Conference in New York, NY
on Tuesday, June 5, 2018 at 1:30 PM EST. Management will also host
investor meetings on Tuesday, June 5, 2018.
- Dr. Neal Walker, President and Chief Executive Officer, will
present at the William Blair 38th Annual Growth Stock Conference in
Chicago, IL on Wednesday, June 13, 2018 at 11:20 PM CT. Management
will also host investor meetings on Wednesday, June 13, 2018.
- Management will participate on panels and host investor
meetings during the 2018 Cantor Dermatology & Aesthetics Summit
in New York, NY on Tuesday, June 19, 2018.
- Management will participate on a panel and host investor
meetings during the 2018 JMP Securities Life Sciences Conference in
New York, NY on Wednesday, June 20, 2018.
A live webcast of the Jefferies 2018 Healthcare Conference
presentation and the William Blair 38th Annual Growth Stock
Conference presentation may be accessed through the Company's web
site, www.aclaristx.com, on the 'Events and Presentations' section.
An archived version of the presentation will be available for 30
days.
About Aclaris
Therapeutics, Inc. Aclaris Therapeutics, Inc. is a
dermatologist-led biopharmaceutical company committed to
identifying, developing, and commercializing innovative therapies
to address significant unmet needs in dermatology, both aesthetic
and medical, and immunology. Aclaris’ focus on market segments with
no FDA-approved medications or where treatment gaps exist has
resulted in the first FDA-approved treatment for raised seborrheic
keratoses and several clinical programs to develop medications for
the potential treatment of common warts, alopecia areata, and
vitiligo. For additional information, please visit
www.aclaristx.com and follow Aclaris on LinkedIn.
Contact:
Aclaris Contact Michael Tung, M.D. Senior Vice
PresidentCorporate Strategy / Investor Relations 484-329-2140
mtung@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024